Histologic categorization of fibrotic cancer stroma in the primary tumor is an independent prognostic index in resectable colorectal liver metastasis

American Journal of Surgical Pathology

Volumn 38, Issue 10, 2014, Pages 1380-1386

  Ueno, Hideki ^a   Konishi, Tsuyoshi ^b   Ishikawa, Yuichi ^b   Shimazaki, Hideyuki ^a   Ueno, Masashi ^b   Aosasa, Suefumi ^a   Saiura, Akio ^b   Hase, Kazuo ^a   Yamamoto, Junji ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Cancer microenvironment; Cancer associated fibroblasts; Colorectal liver metastasis; Desmoplastic reaction; Extracellular matrix

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLASSIFICATION; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; FIBROSIS; HUMAN; JAPAN; KAPLAN MEIER METHOD; LIVER RESECTION; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; STROMA CELL; TIME; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FIBROSIS; HEPATECTOMY; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROMAL CELLS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84908541997     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000232     Document Type: Review

References (33)

1. Sasaki A, Iwashita Y, Shibata K, et al. Analysis of preoperative prognostic factors for long-term survival after hepatic resection of liver metastasis of colorectal carcinoma. J Gastrointest Surg. 2005;9:374-380.
2. Minagawa M, Yamamoto J, Kosuge T, et al. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis. Arch Surg. 2007;142:269-276.
3. Lee W-S, Kim MJ, Yun SH, et al. Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg. 2008;393:13-19.
4. Merkel S, Bialecki D, Meyer T, et al. Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J Surg Oncol. 2009;100:349-357.
5. Beppu T, Sakamoto Y, Hasegawa K, et al. A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2012;19:72-84.
6. Tanaka K, Shimada H, Ueda M, et al. Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol. 2007;14:1336-1346.
7. Tan MCB, Castaldo ET, Gao F, et al. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro- 2-deoxy-D-glucose: role of primary tumor variables. J Am Coll Surg. 2008;206:857-869.
8. Nordlinger B, Guiguet M, Vaillant J-C, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254-1262.
9. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-321.
10. Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford). 2010;12:227-238.
11. Ueno H, Mochizuki H, Hatsuse K, et al. Indicators for treatment strategies of colorectal liver metastases. Ann Surg. 2000;231:59-66.
12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-colon cancer (version 3. 2014) 2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed February 1, 2014.
13. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-252.
14. Allen M, Jones L. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol. 2011;223:162-176.
15. McAllister SS, Weinberg RA. Tumor-host interactions: a farreaching relationship. J Clin Oncol. 2010;28:4022-4028.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
17. Ueno H, Jones A, Jass JR, et al. Clinicopathological significance of the 'keloid-like' collagen and myxoid stroma in advanced rectal cancer. Histopathology. 2002;40:327-334.
18. Ueno H, Jones AM, Wilkinson KH, et al. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 2004;53:581-586.
19. Pietras K, Östman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316:1324-1331.
20. Hewitt RE, Powe DG, Carter GI, et al. Desmoplasia and its relevance to colorectal tumour invasion. Int J Cancer. 1993;53: 62-69.
21. O'Sullivan ST, O'Connor TPF, O'Shaughnessy M. Aetiology and management of hypertrophic scars and keloids. Ann R Coll Surg Engl. 1996;78:168-175.
22. Bran GM, Goessler UR, Hormann K, et al. Keloids: current concepts of pathogenesis (review). Int J Mol Med. 2009;24:283-293.
23. Robles DT, Moore E, Draznin M, et al. Keloids: pathophysiology and management. Dermatol Online J. 2007;13:9.
24. Desmouliè re A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol. 2004;48:509-517.
25. Ueno H, Mochizuki H, Hashiguchi Y, et al. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg. 2004;53:581-586.
26. Wright C, Stewart I. Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol. 2003;27:1393-1406.
27. Müerköster S, Wegehenkel K, Arlt A, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004;64:1331-1337.
28. Shekhar MPV, Santner S, Carolin KA, et al. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol. 2007;170:1546-1560.
29. Ahmed AA, Mills AD, Ibrahim AEK, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007;12:514-527.
30. Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266-4276.
31. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371: 1007-1016.
32. Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252:774-787.
33. Chua TC, Saxena A, Liauw W, et al. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systematic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol. 2010;17:492-501.